MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
DBVT

DBVT

DBV Technologies S.A.

$14.47
-0.05
 (-0.36%)
Exchange:  NASDAQ
Market Cap:  346.093M
Shares Outstanding:  10.819M
Delayed data
Calculate DBVT Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Daniel Tassé
Full Time Employees:  161
Address: 
BAtiment IRO
Châtillon
92320
FR
Website:  https://www.dbv-technologies.com
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company’s pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow’s milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen’s egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn’s disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow’s milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2024/07/30 — Q2 quarter 2024

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue15,72800
Gross Profit15,728-6,813.9420
EBITDA-63,271-110,986.601-139,324
Operating Income-76,432-120,526.718-147,056
Net Income-72,726-113,716.769-146,947

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets182,98665,658233,718
Total Liabilities42,79938,27164,948
Total Stockholders Equity140,18627,388168,770
Total Debt6,5537,79721,683.999
Cash and Cash Equivalents141,36732,456194,167

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-79,653-104,474-121,181
Capital Expenditure-677-2,341-533.642
Free Cash Flow-80,330-106,815-121,181
Net Income-72,726-113,918-146,947
Net Change in Cash-67,827-108,911161,711

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)678,824.402Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,346,175.399Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,006,883Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-269,235.079Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-135,764.880Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-201,376.599Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)42,834.338Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)106,860.329Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)74,308.167Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,840,753.149Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)3,650,394.119Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)2,730,342.409Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.860Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.240Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.500Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
86.11
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-3.79
?Enterprise Value
 (TTM)
: 
340.48M  ?EV/FCF
 (TTM)
: 
-1.99
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-119.47%  ?ROIC
 (TTM)
: 
-97.3%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.14
?P/B
 (TTM)
: 
7.88  ?Current Ratio
 (TTM)
: 
3.72

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about DBVT valuation

Is DBV Technologies S.A. (DBVT) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for DBV Technologies S.A. (DBVT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is DBVT a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DBVT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is DBVT’s P/E ratio?

You can see DBVT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for DBVT?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is DBVT a good long-term investment?

Whether DBVT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

DBVT

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.36
MARKETSnap

Trading Metrics:

Open: 14.56   Previous Close: 14.52
Day Low: 14.3   Day High: 14.56
Year Low: 8.7   Year High: 26.19
Price Avg 50: 14.91   Price Avg 200: 18.14
Volume: 106092   Average Volume: 278407

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
30-07-2026 17:40
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside
23-07-2026 16:46
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
17-07-2026 17:00
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
16-07-2026 19:26
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
16-07-2026 16:10
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
14-07-2026 16:30
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read